11252017Headline:

Lansing, Michigan

HomeMichiganLansing

Email David Mittleman David Mittleman on LinkedIn David Mittleman on Facebook David Mittleman on Avvo
David Mittleman
David Mittleman
Attorney • (888) 227-4770

Eli Lilly Under Fire for Marketing Dangerous Drug to Dementia Sufferers

1 comment

Back in 1995, Eli Lilly sent documents to the FDA showing that Zyprexa, an antipsychotic medication, was not proven effective in alleviating symptoms of dementia in elderly consumers. However, Eli Lilly is now facing lawsuits brought by healthcare insurance providers and pension plans who say the pharmaceutical giant should pay as much as $6.8 billion in damages for downplaying Zyprexa’s health risks after they marketed the drug for an unapproved use, specifically to treat dementia, simply to increase their profits.

During the discovery process of the suit, 10,000 internal Eli documents were unsealed that revealed that Eli Lilly began promoting Zyprexa in earnest to dementia patients, although they reportedly had no less than seven studies that proved that Zyprexa was ineffective for treating dementia. In fact, their studies showed that the drug actually contributed to higher death rates amongst the elderly dementia patients that took it in comparison with patients that took a placebo instead. Nevertheless, Eli Lilly launched an intense endorsement campaign of the drug “behind closed doors”, so to speak, otherwise known as “off label promotion”—promotion of an unapproved use of a particular drug.

Some of Lilly’s promotion techniques included hiring “ghostwriters”, where company officials would write bogus medical journal articles touting “scientific studies” that proved the effectiveness of the drug in elderly dementia patients and then had doctors sign off on the studies. In an even more blatant attempt to promote the drug to dementia patients, Lilly employees compiled a go-to guide of scientists that they knew they could count on to write favorable articles on the drug. Finally, further complicating the mess, Lilly allegedly was in cahoots with CVS Caremark Corp. as well—CVS apparently used its access to doctors to market Zyprexa by offering to send 120,000 letters to these doctors promoting the drug if Lilly agreed to pay $5 per letter. CVS is not a defendant in the suit, and Lilly refuses to state whether or not they accepted the letter-sending offer.

1 Comment

Have an opinion about this post? Please consider leaving a comment or subscribing to the feed to have future articles delivered to your feed reader.

  1. up arrow

    “FIVE at FIVE”

    The Zyprexa antipsychotic drug,whose side effects can include weight gain and diabetes, was sold for “children in foster care, people who have trouble sleeping, elderly in nursing homes.” Five at Five was the Zyprexa sales rep slogan, meaning 5mg dispensed at 5pm would keep patients quiet.
    Google * Eli Lilly Zyprexa * and read the links,this is for a product that we put in our children’s bodies.This drug company has a reputation a little better than a mafia drug lord.

    BTW-I took Zyprexa it gave me diabetes and was as addictive as tobacco.How so?
    Because withdrawal is accompanied by severe insomnia for 6 weeks.It was harder to quit Zyprexa than cigarettes.
    Awful stuff and $10 a pill
    ——-
    Daniel Haszard

    {Eli Lilly is reaping what they have sown!
    The Lilly Zyprexa saga will go on and on and on…..